| 000 | 03552nam a22005057a 4500 | ||
|---|---|---|---|
| 008 | 140202b ck ||||| |||| 00| 0 spa d | ||
| 020 | _a92 4 159469 1 -- 978 92 4 159469 1 | ||
| 082 | 0 | 4 | _a615.85 / W551a |
| 100 | 1 |
_aWHO - World Health Organization _990899 |
|
| 245 | 1 | 0 | _aAntiretroviral therapy for HIV infection in infants and children : towards universal access : |
| 245 | 1 | 0 | _arecommendations for a public health approach / WHO - Worl Health Organization |
| 264 | _aGinebra : WHO - World Health Organization, 2007 | ||
| 300 | _aiv, 144 p. : tablas ; 24 x 16 cm. | ||
| 490 | 0 |
_aHIV/AIDS Programme : Strengthening health services to fight HIV/AIDS _997149 |
|
| 505 | 0 | 0 | _aObjetives of the guidelines -- Development of the guidelines -- Establishing diagnosis of HIV infection - |
| 505 | 0 | 0 | _aWhen to Start Antiretroviral Therapy in Infants and Children -- What to Start - Recommended first-Line ARV |
| 505 | 0 | 0 | _aRegimens in Infants and Children -- Considerations for ART in Infants Previously Exposed to ARV Drugs |
| 505 | 0 | 0 | _a--Atiretroviral drug Toxicity -- Substituting whithin a First-line ARV Regimen in Infants and CHILDREN because |
| 505 | 0 | 0 | _aof Drug Toxicity -- Sitching an ARV Regimen in Infants and Children. Treatment Failure -- Choise of ARV |
| 505 | 0 | 0 | _aRegimens in the Event of Treatment Failure of First-Line Regimens in Infants and Children - Second-Line |
| 505 | 0 | 0 | _aRegimens -- Considerations for infants and children Coinfected With Tuberculosis and HIV -- Considerations for |
| 505 | 0 | 0 | _aNutrition in HIV-infected Infants and Children -- Considerations for ART in Adolescents -- Clinical and |
| 505 | 0 | 0 | _aLaboratory Monitoring -- Adherence to ART -- Strategies in the Event of Failure of Second-Line Regimens -- |
| 505 | 0 | 0 | _aDrug Resistance -- Members of the technical reference group on paediatric HIV care and treatment -- WHO |
| 505 | 0 | 0 | _aclinical staging of HIV for infants and children with established HIV infection -- Presumptive and definitive |
| 505 | 0 | 0 | _acriteria for recognizing HIV related clinical events in infants and children with established HIV infection -- |
| 505 | 0 | 0 | _aWHO classification of HIV-associated immunodeficency in infants and children -- 12 Month mortality risk at |
| 505 | 0 | 0 | _aselected thresholds for %CD4+, absolute CD4 count and total lymphocyte count by age -- Prescribing information |
| 505 | 0 | 0 | _aand weight based dosing of available ARV formulations for infants and children -- Seroius acute and chronic |
| 505 | 0 | 0 | _atoxicities caused by ARV drugs, possibly requiring therapy modification: clinical preenation, laboratory |
| 505 | 0 | 0 | _aabnormalities and implications for ART management -- Severity grading of selected clinical and laboratory |
| 505 | 0 | 0 | _atoxicities most commonly seen with recommended ARV drugs for children -- Sexual maturity rating (Tanner |
| 505 | 0 | 0 | _astaging) in adolescents -- Recommended tiered laboratory capabilities for ART monitoring in resource-limited s |
| 505 | 0 | 0 | _asettings -- References -- |
| 650 | 1 | 4 |
_aAgentes antiretrovirales _xfarmacología _999707 |
| 650 | 1 | 4 |
_aAgentes antiretrovirales _xterapéutica _999707 |
| 650 | 1 | 4 |
_aFarmacologia y terapeutica _9110416 |
| 650 | 1 | 4 |
_aMedicina _9115965 |
| 650 | 1 | 4 |
_aInfecciones del vih _xterapia de droga _9113280 |
| 650 | 1 | 4 |
_aTerapia antiretroviral _9133153 |
| 650 | 1 | 4 |
_aTerapia antiretroviral altamente activa _9133154 |
| 650 | 1 | 4 |
_aTerapias _9133213 |
| 650 | 1 | 4 |
_aSalud _9130891 |
| 700 | 1 |
_aOMS - Organización Mundial de la Salud (Ginebra) _971253 |
|
| 999 |
_c24420 _d24420 |
||